Novartis Shares Drop After Third Clinical Trial Setback This Week
Macro·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Novartis (NOVN) shares are lower as it suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study.
Boston Scientific (BSX) shares are moving on news it said that fallout from a cybersecurity issue is impacting its operations.
NovartisBoston Scientific
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“On this episode of Stock Movers:”
Bloomberg — Novartis and Boston Scientific Slide, Intel Price Hikes | Stock Movers